Fidelity Advisor Biotechnology Z holds a quantitatively derived Silver Morningstar Medalist Rating. The rating reflects that it has scored well on factors Morningstar research associates with future outperformance relative to category peers.
Fidelity Advisor Biotechnology Fund - Class Z FIJYX
- NAV / 1-Day Return 51.10 / +1.67 %
- Total Assets 2.2B
-
Adj. Expense Ratio
0.580%
- Expense Ratio 0.580%
- Distribution Fee Level Low
- Share Class Type Institutional
- Category Health
- Investment Style Mid Blend
- Min. Initial Investment 0
- Status Open
- TTM Yield 0.99%
- Turnover 51%
USD | NAV as of Jul 18, 2026 | 1-Day Return as of Jul 18, 2026, 4:47 AM GMT+0
Morningstar’s Analysis FIJYX
Will FIJYX outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 50.0
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
AbbVie Inc | 14.76 | 281M | Healthcare |
Gilead Sciences Inc | 6.57 | 125M | Healthcare |
Alnylam Pharmaceuticals Inc | 5.39 | 103M | Healthcare |
Dianthus Therapeutics Inc | 3.57 | 68M | Healthcare |
Insmed Inc | 3.47 | 66M | Healthcare |
argenx SE ADR | 3.39 | 65M | Healthcare |
Cogent Biosciences Inc | 3.37 | 64M | Healthcare |
Spyre Therapeutics Inc | 3.31 | 63M | Healthcare |
Ascendis Pharma AS | 3.17 | 60M | Healthcare |
Biogen Inc | 3.03 | 58M | Healthcare |
United States